TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Renal clearance of N-oxide-zopiclone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bacteriological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color stability of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic form evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual function 12 months postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Geometric Mean Concentrations (GMCs) of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates (SRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy in patients with AF/AFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean systolic pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean diastolic pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive performance on visual n-back task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge on the prevention of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CD4+ T cells specific to vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Altered β-catenin expression in primary tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in CIN lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved Pap smear results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Colposcopy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for reoperation or transfusion for extraluminal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: pain-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to app usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Regular dilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in mouth aperture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iliocapsularis muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: iliocapsularis muscle fatty infiltration prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean leg volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg symptoms performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Rhinoconjunctivitis Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest pain during pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myofibrillar protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: take-home baby rate
Endpoint domain: Mortality/survival
Primary endpoint: Bioequivalence of Clindox® to Dalacin C®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms measured by PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured by QLS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Constipation response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global sense response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systolic Arterial Pressure (SAP) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Arterial Pressure (DAP) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in mean total Adult ADHD Investigator Symptom Report Scale (AISRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of blood gene expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Iron status of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intrapatient coefficient of variation (CV) in 24-h UFC measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete response rate in acute emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of CD64 molecule on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Density of CD163 molecule on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of hysteroscopy in diagnosing endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of endometrial diagnostic categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with insufficient tissue for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: substantial functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total doses of heparin and protamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volume of homologous blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood products exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in mPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best-corrected visual acuity (BCVA) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA maximum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA expansion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score including 28 joints using C-reactive protein (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IgG to P. gingivalis hemin binding protein (HBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of citrulline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent rate
Endpoint domain: Adverse events/effects
Primary endpoint: International normalized ratio (INR) and prothrombin time (PT) areas under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MAS classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in GMFM-88 total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1 stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence or recurrence of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD11b expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: poor mental health outcomes in adulthood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in peak number of standard drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in blood alcohol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression product appraisal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depression product purchasing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Suppression of apoptosis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tonographic outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache relief at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Delta area under the curve of glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postocclusive LDF parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heat foot LDF parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heat arm LDF parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective function of the knee
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: anteroposterior knee stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive status maintenance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Affective status maintenance or improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful ventilation with BIPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival rate of high‐flexion mobile‐bearing TKA
Endpoint domain: Mortality/survival
Primary endpoint: worsened survival
Endpoint domain: Mortality/survival
Primary endpoint: MABC total impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emergence of drug-resistant virus
Endpoint domain: Adverse events/effects
Primary endpoint: risk of gestational hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-sudden death
Endpoint domain: Mortality/survival
Primary endpoint: Non-sustained ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Genital warts
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heavy drinking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative alcohol consequences
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day death/myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Wheelchair Skills Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted increase in total ADR reporting rates
Endpoint domain: Adverse events/effects
Primary endpoint: Severe pregnancy and post-partum complications
Endpoint domain: Adverse events/effects
Primary endpoint: PaO2/FIO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in QuickDASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of EPT vs SR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of partners treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median time-to-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of the risks of tonsillectomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Awareness of tooth damage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of tonsillectomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of ECPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: histopathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-ERCP pancreatitis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Cobb angle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of chronic allograft nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Negative mycological results at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global response (mycological and clinical cure) at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of transverse foramen of C4 and C6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virologic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: serum bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction of exchange transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of fractures in children with elbow injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative risk of fracture in children with nonclassic history
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of spontaneous erection sufficient for satisfactory sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Coronary bypass graft occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: BPAR (Biopsy-Proven Acute Rejection)
Endpoint domain: Adverse events/effects
Primary endpoint: CsA toxicity lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody-mediated rejection
Endpoint domain: Adverse events/effects
Primary endpoint: television viewing reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Falls efficacy scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS‐2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS‐3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini‐BESTest score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates (HAM-D score of 7 or less)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of skin elasticity and tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of folds and wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: inflammatory markers (high‐sensitivity C‐reactive protein, interleukin‐6, matrix metalloproteinase‐9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Craving scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-10 levels 24 and 48 hours after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participation rates in the obesity intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24 hours' average heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour use of hip protectors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: prevalence of symptomatic diffuse atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall fidelity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of the recurrence periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual contamination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in haemoglobin A(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: knee angle at seat-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak vertical force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean shimmer scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean nutritional quality of purchased items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Atelectatic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total stroke
Endpoint domain: Mortality/survival
Primary endpoint: PPG AUC0-180 change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nonpulmonary organ failure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of 20 or more small, hard macular drusen per eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning peak expiratory flow (mPEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of clinical hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of clinically serious hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Function (SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in state anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: induction-to-abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean MRSE at 90 days postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of malondialdehyde in plasma and erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall risk of complications
Endpoint domain: Adverse events/effects
Primary endpoint: risk of minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Static ground reaction force of the paretic limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic ground reaction force of the paretic limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skating time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes